The importance of the disease-free survival (DFS) endpoint to survivors of lung cancer Source: Virtual Congress 2021 – Screening, diagnosis, management and prognosis of lung cancer Year: 2021
Progression-free survival with first line treatment as prognostic factor of treatment success in subsequent lines in lung adenocarcinoma patients – who´s the „good responder“? Source: Virtual Congress 2021 – Therapy of lung cancer Year: 2021
Impact on recurrence and long-term survival Source: Annual Congress 2004 - Impact of neoadjuvant treatments on morbidity and oncological outcome of patients with NSCLC Year: 2004
Determining values of prognostic factors with patients with NSCLC based on two years survival Source: Annual Congress 2007 - Lung neoplasms Year: 2007
Tumor stage and survival critical comparison of survival data obtained from a field study with those from the literature Source: Eur Respir J 2002; 20: Suppl. 38, 268s Year: 2002
Brain metastasis as initial presentation of lung cancer - Impact of prognostic factors on patient survival Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside Year: 2017
Increased serum placenta growth factor level is significantly associated with progression, recurrence and poor prognosis of lung cancer Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012
Telomere length and genetic variant associations with interstitial lung disease progression and survival Source: Eur Respir J, 53 (4) 1801641; 10.1183/13993003.01641-2018 Year: 2019
Survival predictors Source: International Congress 2016 – The stage I non-small-cell lung cancer Year: 2016
Rates of treatment response and median survival in advanced non small cell lung cancer patients Source: Eur Respir J 2004; 24: Suppl. 48, 302s Year: 2004
Gender-dependent predictors for survival in patients with COPD Source: International Congress 2019 – Phenotypes and comorbidities of airway diseases Year: 2019
Clinical and biological predictors of progression-free survival (PFS) and overall survival (OS) in patients (pts) with advanced non-small-cell lung cancer (NSCLC) treated by erlotinib in the ERMETIC cohort Source: Annual Congress 2010 - The role of biomarkers in lung cancer Year: 2010
Importance of CYFRA-21 in estimation of survival of patients with NSCLC Source: Eur Respir J 2006; 28: Suppl. 50, 85s Year: 2006
Analysis of the ability of different health status and dyspnea measures to predict 5-year mortality in COPD Source: Eur Respir J 2002; 20: Suppl. 38, 251s Year: 2002
Effect of primary cilium-associated genes expression on the survival of mesothelioma patients: In silico investigation of TCGA data. Source: Virtual Congress 2020 – Novel directions in pleural disease: bench to bedside Year: 2020
Clinical factors of long-term survival in patients with advanced lung cancer Source: International Congress 2017 – Lung cancer: clinically relevant aspects of epidemiology, co-morbidities, metastasised disease and follow-up Year: 2017
Limited role of Ki-67 in lung carcinoid tumor patients predicting overall short-term survival,A single institution experience Source: International Congress 2018 – Lung cancer: novel prognostic markers and scores Year: 2018
Serum microRNA signatures identified in a genome-wide profiling predict the mortality of patients with sepsis Source: Annual Congress 2011 - New aspects in prevention and treatment of community-acquired pneumonia and lower respiratory tract infections Year: 2011
Surrogate markers predicting overall survival for lung cancer: ELCWP recommendations Source: Eur Respir J 2011; 39: 9-28 Year: 2012
Surrogate markers predicting overall survival for lung cancer: ELCWP recommendations Source: Eur Respir J 2012; 39: 9-28 Year: 2012